Outlook Therapeutics Says Resubmission Of ONS-5010 Biologics License Application On Track For Q1 CY2025
Portfolio Pulse from Benzinga Newsdesk
Outlook Therapeutics announced that the resubmission of its Biologics License Application (BLA) for ONS-5010 is on track for Q1 CY2025.
August 14, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Outlook Therapeutics is on track to resubmit its Biologics License Application for ONS-5010 in Q1 CY2025, which could be a significant milestone for the company.
The resubmission of the BLA for ONS-5010 is a critical step for Outlook Therapeutics. If approved, it could lead to significant revenue opportunities. The market is likely to react positively to this progress update.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100